GREY:ATBPF - Post Discussion
Post by
Duster340 on Feb 15, 2023 9:19am
Predictable Delays
but the update is very promising, i do not think the stock will go lower, it already is priced dirt cheap. if there is a dip i am sure it will be bought up imediatley. i will be a buyer
#1 burnt through less cash
#2 made progress on IBD
#3 a potential 1mil more from citagenix
Business Highlights and Operational Update Progress for otenaproxesul on formulation and IP - Transitioned to faster-dissolving formulation that accelerates onset of action; also enables treatment regimens with lower drug doses, providing additional safety buffer and a potential pathway to address chronic pain indications
- Filed patent application for new formulation, strengthening IP protection to 2043
- Initiated animal de-risking studies for new formulation; saved resources by bypassing previously planned molar extraction clinical study
- Finalized study design for upcoming pharmacokinetic/pharmacodynamic ("PK/PD") study in healthy volunteers to confirm dose selection for upcoming Phase II bunionectomy trial; PK/PD study anticipated to take 2 – 3 months
- Results from DILIsym, a sophisticated software model widely used to predict liver safety, suggest that all envisioned acute pain treatment regimens of the new formulation are liver-safe for five-day treatment durations (including ten days post treatment follow up)
- Retained Klick Health, a leading life science-focused marketing and commercialization agency, to conduct a comprehensive strategic positioning assessment of otenaproxesul for acute pain in the U.S. market; based on the recent third-party commercial assessment projecting U.S. market peak annual sales exceeding $1 billion, the purpose of the current study is to validate the drug’s positioning and formulate a commercial launch strategy to support partnering discussions
- Continued investigation of alternative formulations and treatment regimens as potential paths forward for chronic pain indications
Be the first to comment on this post